Program
YTS109
A development code. Also written as “YTS109 cell” and “YTS109 cell injection”.
Its studies are mostly in Lupus Nephritis · Anemia, Hemolytic, Autoimmune · Lupus Erythematosus, Systemic, led by China Immunotech (Beijing) Biotechnology.
Furthest: phase 1, since Apr 16, 20258 company-led studies, 6 open or runningNext primary completion: Nov 24, 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| China Immunotech (Beijing) Biotechnology | 86 open or running | phase 1since Apr 16, 2025 | Apr 16, 2025 | Nov 24, 2026phase 1 · NCT07236762 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 16, 2025First study: phase 1 study in Lupus NephritisFirst studyNCT06943937 · 2 enrolled · China
- May 9, 2025Phase 1 study in Lupus Erythematosus, SystemicNCT06978647 · 12 planned · China
- Jul 11, 20252 phase 1 studiesNCT07075484, NCT07104721
- Aug 8, 2025Phase 1 study in Lupus Erythematosus, SystemicNCT07123519 · 18 planned · China
- Nov 15, 20252 phase 1 studies in Lupus Erythematosus, SystemicNCT07236801, NCT07236762
- Mar 2, 2026Phase 1 study in Anemia, Hemolytic, AutoimmuneNCT07453836 · 13 planned · China
Ahead
- Nov 13, 2026Primary completion: phase 1 study in Lupus Erythematosus, SystemicNCT07236801
- Nov 24, 2026Primary completion: phase 1 study in Lupus Erythematosus, SystemicNCT07236762
- Mar 18, 2027Primary completion: phase 1 study in Anemia, Hemolytic, AutoimmuneNCT07453836
- May 19, 2027Primary completion: phase 1 study in Lupus Erythematosus, SystemicNCT06978647
TargetBeta
CD19 →read by rule
“YTS109 is a universal allogeneic CD19-targeting STAR-T cell therapy designed to efficiently eliminate CD19+ B cells and attenuate pathogenic autoimmune responses.”study text, by rule · the study
Other programs on CD19
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| blinatumomabrule | Amgen | phase 4 | 29 |
| inebilizumabrule | Amgen | phase 4 | 19 |
| Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F | AstraZeneca | phase 3 | 12 |
| axicabtagene ciloleucelrule | Gilead Sciences | phase 3 | 10 |
| surovatamig | AstraZeneca | phase 3 | 10 |
| lisocabtagene maraleucelrule | Bristol-Myers Squibb | phase 3 | 10 |
| Anti-CD19/CD3 Bispecific Antibody MK-1045 | Merck | phase 3 | 8 |
| obexelimab | zenas-biopharma-usa-llc | phase 3 | 7 |
| Autologous Anti-CD19 CAR-T Cells CABA-201rule | cabaletta-bio | phase 3 | 6 |
| zolacabtagene autoleucel | Bristol-Myers Squibb | phase 3 | 6 |
| Autologous Anti-CD19/Anti-CD20 CAR-T Cells KITE-753rule | Gilead Sciences | phase 3 | 2 |
| rondecabtagene autoleucelrule | lyell-immunopharma-inc | phase 3 | 2 |
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07453836Anemia, Hemolytic, Autoimmune · China | 1 | Not yet recruiting | Mar 18, 2027 | 13 |
| NCT07236801Lupus Erythematosus, Systemic · China | 1 | Recruiting | Nov 13, 2026 | 18 |
| NCT07236762Lupus Erythematosus, Systemic · China | 1 | Recruiting | Nov 24, 2026 | 18 |
| NCT07123519Lupus Erythematosus, Systemic · China | 1 | Recruiting | Aug 13, 2027 | 18 |
| NCT07104721Lupus Erythematosus, Systemic · China | 1 | Recruiting | Aug 4, 2026 | 18 |
| NCT07075484Anemia, Hemolytic, Autoimmune · China | 1 | Completed | Dec 30, 2025 | 7 |
| NCT06978647Lupus Erythematosus, Systemic · China | 1 | Recruiting | May 19, 2027 | 12 |
| NCT06943937Lupus Nephritis · China | 1 | Terminated | Apr 25, 2026 | 2 |
How it is read
Names in the registry
- “YTS109 cell”, 7 entries
- “YTS109 cell injection”, 1 entry
Codes read as this program: YTS109.
Conditions, from the studies’ own filings
- Lupus Nephritis, 4 studies
- Anemia, Hemolytic, Autoimmune, 2 studies
- Lupus Erythematosus, Systemic, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.